InnoPharmax, Inc.

Detailed Description

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of infectious diseases, immunology, oncology, and other specialties in Taiwan. The company offers anti-infection agents, including Bestnem, an imipenem and cilastatin sodium solution that is used intravenous in the treatment of various infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, or bone and joint infections; and various complicated or uncomplicated urinary tract infections, septicemia, or endocarditis caused by susceptible organisms. It also provides gadopentetate dimeglumine, a contrast medium for magnetic resonance imaging (MRI) of the body after intravenous administration; and gadodiamide, a contrast medium for cranial and spinal MRI, as well as for general MRI of the body after intravenous administration. In addition, the company offers oncology agents comprising Innomustine for the treatment of hodgkin's disease, non-hodgkin's lymphoma, and plasmocytoma, as well as chronic lymphocytic leukemia and breast cancer; and immunological agents that include Cyclosporine A, an immuno-suppresant with a low aqueous solubility used for the inhibition of graft rejection in organ transplant recipients, as well as inpheno tablets. Further, it is developing oncology, cardiovascular, CNS, urology, and contrast agents, as well as agents for metabolic disorders and drugs for rare diseases. The company was founded in 2005 and is based in Taipei City, Taiwan. InnoPharmax Inc. is a subsidiary of Synmosa Biopharma Corporation.